201 related articles for article (PubMed ID: 33804659)
1. Synthesis and Biological Evaluation of 2,3,4-Triaryl-1,2,4-oxadiazol-5-ones as p38 MAPK Inhibitors.
Romeo R; Giofrè SV; Chiacchio MA; Veltri L; Celesti C; Iannazzo D
Molecules; 2021 Mar; 26(6):. PubMed ID: 33804659
[TBL] [Abstract][Full Text] [Related]
2. Azastilbenes: a cut-off to p38 MAPK inhibitors.
Poon JF; Alao JP; Sunnerhagen P; Dinér P
Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
5. A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia.
Willemen HL; Campos PM; Lucas E; Morreale A; Gil-Redondo R; Agut J; González FV; Ramos P; Heijnen C; Mayor F; Kavelaars A; Murga C
Biochem J; 2014 May; 459(3):427-39. PubMed ID: 24517375
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel Substituted N,N'-Diaryl ureas as Potent p38 Inhibitors.
Zhu D; Li X; Zhong W; Zhao D
Molecules; 2015 Sep; 20(9):16604-19. PubMed ID: 26378516
[TBL] [Abstract][Full Text] [Related]
7. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
Pinsetta FR; Taft CA; de Paula da Silva CH
J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842
[TBL] [Abstract][Full Text] [Related]
8. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM
Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
[TBL] [Abstract][Full Text] [Related]
10. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
Park H; Lee S; Hong S
Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
[TBL] [Abstract][Full Text] [Related]
12. Identification of benzimidazole containing 4
Lakshmanan K; Byran G
J Recept Signal Transduct Res; 2021 Apr; 41(2):153-158. PubMed ID: 32752909
[TBL] [Abstract][Full Text] [Related]
13. Substituted Benzamides from Anti-inflammatory and p38 Kinase Inhibitors to Antitubercular Activity: Design, Synthesis and Screening.
Kulkarni R; Mitkari U; Achaiah G; Laufer S; Bikshapti DVRN; Chandrashekar VM; Gurav PB; Joshi SJ; Chipade VD
Mini Rev Med Chem; 2018; 18(17):1486-1497. PubMed ID: 28685700
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents.
Ma Z; Pan Y; Huang W; Yang Y; Wang Z; Li Q; Zhao Y; Zhang X; Shen Z
Bioorg Med Chem Lett; 2014 Jan; 24(1):220-3. PubMed ID: 24332090
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685
[TBL] [Abstract][Full Text] [Related]
17. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
[TBL] [Abstract][Full Text] [Related]
18. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
